Want to see PMHS full AI Analyst Report?
Top Page
Polomar Health Services
(OTC:PMHS)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.16
▼(-18.50% Downside)
Action:Reiterated
Date:09/26/26
The score is primarily weighed down by very weak financial performance—massive operating/net losses, negative equity, and negative free cash flow—despite strong revenue growth and healthy gross margin. Technical indicators also lean bearish (negative MACD, RSI below 50, and price below key moving averages). Valuation is difficult to support due to losses (negative P/E) and no dividend yield.
Positive Factors
Revenue and Gross Margin
TTM revenue growth of about 92% alongside a roughly 61% gross margin shows that Polomar is generating meaningful sales and retaining substantial gross profit. If maintained, this provides a stronger base for eventual operating leverage, although current costs still absorb it.
Negative Factors
Extreme Operating Losses
Extremely negative operating and net margins show that Polomar’s current cost structure is not scaling with revenue. The company retains gross profit, but operating expenses and other costs overwhelm it, leaving limited evidence that growth is translating into sustainable earnings over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Gross Margin
TTM revenue growth of about 92% alongside a roughly 61% gross margin shows that Polomar is generating meaningful sales and retaining substantial gross profit. If maintained, this provides a stronger base for eventual operating leverage, although current costs still absorb it.
Read all positive factors
Polomar Health Services (PMHS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.82M
Dividend YieldN/A
Average Volume (3M)7.82K
Price to Earnings (P/E)―
Beta (1Y)-1.12
Revenue Growth7688.77%
EPS Growth-359.43%
CountryUS
Employees7
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,380,869
10 Day Avg. Volume11,234
30 Day Avg. Volume7,823
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-18.17
Price to Sales (P/S)34.26
P/FCF Ratio-56.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Polomar Health Services Business Overview & Revenue Model
Company Description
Polomar Health Services, Inc. operates as a retail compounding pharmacy. The company owns SlimRx, a weight loss focused online platform connects patients with licensed physicians to prescribe weight loss medications, such as semaglutide compounded...
How the Company Makes Money
null...
Polomar Health Services Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.17M | 648.23K | 58.82K | 0.00 | 34.53K | 0.00 |
| Gross Profit | 1.94M | 460.10K | 30.90K | 0.00 | 34.53K | 0.00 |
| EBITDA | -85.97K | -776.94K | -1.04M | -146.67K | -181.45K | -132.75K |
| Net Income | -9.46M | -10.70M | -1.34M | -416.50K | -181.12K | -168.40K |
Balance Sheet | ||||||
| Total Assets | 814.73K | 390.04K | 9.95M | 244.00 | 261.48K | 0.00 |
| Cash, Cash Equivalents and Short-Term Investments | 178.87K | 132.15K | 6.19K | 244.00 | 225.62K | 0.00 |
| Total Debt | 794.79K | 14.86K | 49.18K | 81.66K | 69.70K | 32.69K |
| Total Liabilities | 1.87M | 1.61M | 14.86K | 13.78K | 74.72K | 35.65K |
| Stockholders Equity | -1.06M | -1.22M | 9.94M | -13.54K | 186.77K | -35.65K |
Cash Flow | ||||||
| Free Cash Flow | -6.96K | -396.00K | -1.11M | -371.86K | -40.93K | -32.69K |
| Operating Cash Flow | -6.96K | -396.00K | -1.02M | -371.86K | -40.93K | -32.69K |
| Investing Cash Flow | 0.00 | 0.00 | -90.89K | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 181.15K | 521.95K | 1.11M | 146.49K | 266.55K | 32.69K |
Polomar Health Services Technical Analysis
Negative
0.20
Price Trends
0.18
Negative
0.17
Negative
0.25
Negative
Market Momentum
-0.01
Positive
46.16
Neutral
40.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PMHS, the sentiment is Negative. The current price of 0.2 is below the 20-day moving average (MA) of 0.20, above the 50-day MA of 0.18, and below the 200-day MA of 0.25, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 46.16 is Neutral, neither overbought nor oversold. The STOCH value of 40.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PMHS.
Polomar Health Services Risk Analysis
Polomar Health Services disclosed 47 risk factors in its most recent earnings report. Polomar Health Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Polomar Health Services Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $4.12M | -0.08 | -125.01% | ― | ― | 93.91% | |
43 Neutral | $23.87M | -1.39 | -3.48% | ― | -8.04% | -100.01% | |
42 Neutral | $4.82M | -0.26 | -892.31% | ― | 7688.77% | -359.43% | |
42 Neutral | $2.97M | -0.09 | -72.87% | ― | ― | ― | |
38 Underperform | $1.62M | -0.02 | -46.21% | ― | -35.26% | 51.06% |
* Healthcare Sector Average
PMHS
Polomar Health Services
0.17
-0.03
-15.00%
PRFX
PainReform
0.95
-6.06
-86.50%
UPC
Universe Pharmaceuticals
4.52
0.32
7.62%
BJDX
Bluejay Diagnostics
0.94
-5.14
-84.56%
NIVF
NewGenIvf Group
0.07
-966.53
-99.99%
MNDR
Mobile-health Network Solutions Class A
1.25
-24.31
-95.11%
Polomar Health Services Corporate Events
Business Operations and StrategyExecutive/Board Changes
Polomar Health Services Appoints Douglas Beck as CFO
Positive
Jul 20, 2026
On July 15, 2026, Polomar Health Services, Inc. appointed Douglas Beck as Chief Financial Officer and Treasurer, with Beck also assuming the roles of principal financial officer and principal accounting officer as of that date. The appointment ref...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Polomar Health Services Overhauls Board and Governance Structure
Positive
Jul 6, 2026
Effective July 1, 2026, Polomar Health Services restructured its board, with David Spiegel and Terrence M. Tierney resigning as directors and four new directors – George Hornig, Alexandra Peterson, Gabrielle Toledano and George Caruolo ̵...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.